Why The Traditional Approach To Evaluating Gene Editing Is Not Your Only Option

By Larry Lockwood, Chief Commercial Officer

Evaluating genetic therapies shouldn't force drug developers into rigid binary choices between costly internal infrastructure or restrictive, single-technology partnerships before biological viability is even proven. Because no single editor or delivery system solves every genetic target, adopting an iterative, decision-driven framework reduces technical and financial risk step-by-step. De-coupling feasibility testing from long-term capital commitments allows teams to rapidly generate objective go/no-go data.

Once feasibility is validated, focus seamlessly pivots to optimizing potency, specificity, and delivery to establish a clinical-ready candidate. Stacking these insights across a broad portfolio transforms isolated efforts into a scalable engine for therapeutic success.